Loading
Showed that giving an ALK pill after surgery, instead of chemotherapy, sharply reduces recurrence, including in the brain.
ALINA, trial NCT03456076 sponsored by Roche and reported in 2023, showed that two years of the ALK inhibitor alectinib after surgery, instead of platinum chemotherapy, sharply reduces recurrence in resected stage IB to IIIA ALK-positive non-small-cell lung cancer, including recurrence in the brain. It enrolled 257 patients, met its primary disease-free survival endpoint in stage II to IIIA disease with a large reduction in the risk of recurrence, also reduced central nervous system recurrence, and led to FDA approval in April 2024. OnCo links it to ALK as a target, to alectinib and to ADAURA, whose adjuvant osimertinib template it follows for a second oncogene. Overall survival data are immature, so whether delaying recurrence translates into more cures is the open question. Alectinib has its own page.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
257 enrolled.
Median not reached
SourceStep lines join published landmark estimates; the true curve between them is not shown.
Curves show the trial population; they are not a prediction for any one person.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease-free survival, stage II to IIIAprimary | Alectinib | 116 | Median not reached | 0.24 (0.13 to 0.45) | <0.001 | link |
| Platinum chemotherapy | 115 | 44.4 months |
Shares Alectinib, ALK-positive non-small-cell lung cancer, ALK, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall.
Shares Alectinib, ALK-positive non-small-cell lung cancer, ALK, Roche / Genentech.
Shares Alectinib in resected ALK-positive non-small-cell lung cancer, Alectinib, ALK-positive non-small-cell lung cancer, ALK.
Shares ALK-positive non-small-cell lung cancer, ALK, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, Small-molecule kinase inhibitors.
Shares Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [, ADAURA, Resectable stage I to III non-small-cell lung cancer, Lung cancer (all types).
Shares Alectinib, ALK-positive non-small-cell lung cancer, ALK, Lung cancer (all types).
Shares Alectinib, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Alectinib, Resectable stage I to III non-small-cell lung cancer, Roche / Genentech, Non-small-cell lung cancer.